Louisiana State Employees Retirement System Sells 12,300 Shares of Illumina, Inc. (NASDAQ:ILMN)

Louisiana State Employees Retirement System lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 21.8% during the 4th quarter, Holdings Channel reports. The fund owned 44,000 shares of the life sciences company’s stock after selling 12,300 shares during the period. Louisiana State Employees Retirement System’s holdings in Illumina were worth $5,880,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ILMN. Empowered Funds LLC raised its stake in shares of Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after acquiring an additional 66 shares in the last quarter. Caprock Group LLC grew its holdings in Illumina by 3.0% in the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after purchasing an additional 83 shares during the last quarter. Integrated Advisors Network LLC increased its position in shares of Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares in the last quarter. Stephens Inc. AR lifted its holdings in shares of Illumina by 1.4% during the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after purchasing an additional 90 shares during the last quarter. Finally, Moors & Cabot Inc. boosted its position in shares of Illumina by 1.7% in the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock worth $759,000 after purchasing an additional 95 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ILMN shares. TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and reduced their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. UBS Group lifted their target price on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Citigroup lowered shares of Illumina from a “buy” rating to a “neutral” rating and cut their price target for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. Finally, Piper Sandler lifted their price objective on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and a consensus target price of $159.45.

Illumina Price Performance

NASDAQ:ILMN opened at $103.57 on Thursday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The company has a 50 day moving average price of $135.10 and a 200-day moving average price of $135.34. Illumina, Inc. has a 1-year low of $99.35 and a 1-year high of $156.66. The firm has a market cap of $16.43 billion, a price-to-earnings ratio of -13.49 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. Equities research analysts forecast that Illumina, Inc. will post 4.42 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.